IN THE CLAIMS:

This listing of claims will replace all prior versions and listing of claims in the application.

Listing of claims:

Claim 1 **(currently amended)**: A compound of the formula **(IA), (IB), (IC), (ID), (IE)** and **(IF)** of the generic structure of formula **(I)**:



(I)

wherein:

i) a compound of formula **(IA)** is selected from:



(IA)

wherein:

R^1 is 2-(pyrazolyl-1-yl)ethyl, 3-(isoxazol-3-yloxy)propyl, 2-(thiazol-3-yloxy)ethyl, 2-(thiadiazol-3-yloxy)ethyl, 1,3-dihydroxyprop-2-yl, 1-methyl-1-hydroxymethylethyl, 1,2-dimethylpropyl, 1-methylcyclopropyl, 2,2-dimethylaziridin-1-yl, *t*-butyl, 2-morpholino-1,1-dimethylethyl, 2-pyrrolidin-1-yl-1,1-dimethylethyl,

2-methylthio-1,1-dimethylethyl, 1,3-dimethoxyprop-2-yl, 1-methoxyprop-2-yl, 1-hydroxyprop-2-yl, 1-ethoxyprop-2-yl, 1-propoxyprop-2-yl, ethoxyethyl or 2-methoxy-1,1-dimethylethyl; and

~~**R**^{1} is 2-(pyrazolyl-1-yl)ethyl, 3-(isoxazol-3-yloxy)propyl, 2-(isothiazol-3-yloxy)ethyl, 2-(thiadiazol-3-yloxy)ethyl, 1,3-dihydroxyprop-2-yl, 1-methyl-1-hydroxymethylethyl, 1,1-dimethylpropyl, 1-methylcyclopropyl, *t*-butyl, 2-morpholino-1,1-dimethylethyl, 2-pyrrolidin-1-yl-1,1-dimethylethyl, 2-methylthio-1,1-dimethylethyl, 1,3-dimethoxyprop-2-yl, 1-methoxyprop-2-yl, 1-hydroxyprop-2-yl, 1-ethoxyprop-2-yl, 1-propoxyprop-2-yl, ethoxyethyl or 2-methoxy-1,1-dimethylethyl; and~~

R^2 is hydrogen;

~~or R^1 and R^2 together form 2,2-dimethylaziridin-1-yl;~~

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof;

ii) a compound of formula **(IB)** is selected from:



(IB)

wherein:

R^1 is pyrid-2-ylmethyl, 2-(2-methyl-1,2,4-triazol-5-yl)ethyl, 2-pyrid-2-ylethyl, 2-pyridazin-3-ylethyl, 2-(3,5-dimethyltriazol-4-yl)ethyl, 2-pyrid-3-ylethyl, 2-methoxyethyl, 3-(5-methylpyrazol4-yl)propyl, 2-trifluoromethylpyrid-5-ylmethyl, 2-pyridazin-4-ylethyl, 1,1-dimethylpropyn-2-yl or 2-ethoxyethyl; and

~~**R**^{1} is pyrid-2-ylmethyl, 2-(2-methyl-1,2,4-triazol-5-yl)ethyl, 2-pyrid-2-ylethyl, 2-pyridazin-3-ylethyl, 2-(3,5-dimethyltriazol-4-yl)ethyl, 2-pyrid-3-ylethyl, 2-methoxyethyl, 3-(5-methylpyrazol4-yl)propyl, 2-trifluoromethylpyrid-5-ylmethyl,~~

~~2-pyridazin-4-ylethyl, 1,1-dimethylprop-2-ynyl, 2-ethoxyethyl, 2-phenoxyethyl, 2-(4-methoxyphenoxy)ethyl, 2-(2-methoxyphenoxy)ethyl, 2-(vinyloxy)ethyl, 2-(isopropoxy)ethyl and 2-(propoxy)ethyl; and~~

R^2 is hydrogen or cyano;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof;

provided that when R^1 is 2-methoxyethyl, R^2 is cyano;

iii) a compound of formula **(IC)** is selected from:



~~(IC)~~



(IC)

wherein:

R^1 is hydrogen, ~~heterocyclyl,~~ C_{1-6}alkyl or C_{1-6}alkoxyC_{1-6}alkyl; ~~wherein R^1 may be optionally substituted on carbon by one or more hydroxy, carboxy, C_{1-6}alkoxy, C_{1-6}alkoxycarbonyl, *N,N*-(C_{1-6}alkyl)$_2$amino, heterocyclyl, C_{3-6}cycloalkyl and C_{1-6}alkoxyC_{1-6}alkoxy; and wherein if a heterocyclyl contains an -NH- moiety, that nitrogen may be optionally substituted by C_{1-6}alkyl or benzyl;~~

R^2 is hydrogen, halo or cyano;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof;

provided that when R^1 is 2-methoxyethyl, ~~cyclopropylmethyl or pyrid-2-ylmethyl,~~ R^2 is not hydrogen;

iv) a compound of formula **(ID)** is selected from:



(ID)

wherein:

R^1 is hydrogen, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkylC_{1-3}alkyl, a heterocyclyl or heterocyclylC_{1-3}alkyl; wherein R^1 may be optionally substituted on carbon by one or more methyl, ethyl, methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethoxy or cyclopropylmethoxy; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by one or more methyl, ethyl, acetyl, 2,2,2-trifluoroethyl or methoxyethyl;

R^2 is hydrogen, halo or cyano;

R^3 is C_{2-6}alkyl;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof;

v) a compound of formula **(IE)** is selected from:



(IE)

wherein:

R^1 is hydrogen, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkylC_{1-3}alkyl, a heterocyclyl or heterocyclylC_{1-3}alkyl; wherein R^1 may be optionally substituted on

carbon by one or more methyl, ethyl, methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethoxy or cyclopropylmethoxy; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by one or more methyl, ethyl, acetyl, 2,2,2-trifluoroethyl or methoxyethyl;

R^2 is halo, cyano, C_{1-3}alkyl or C_{1-3}alkoxy;

p is 1-2; wherein the values of R^2 may be the same or different;

R^3 is hydrogen, halo or cyano;

R^4 is C_{1-4}alkyl;

~~**R^5** is C_{1-6}alkyl or C_{2-6}alkenyl; wherein R^5 may be optionally substituted on carbon by one or more methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethoxy or cyclopropylmethoxy;~~

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof;

provided that said compound is not

4-(1,2-dimethylimidazol-5-yl)-2-[2-methoxy-4-(*N*-methylsulphamoyl)-5-methylanilino] pyrimidine;

vi) a compound of formula **(IF)** is selected from:



(IF)

wherein:

R^1 is C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkylC_{1-3}alkyl, a heterocyclyl or heterocyclylC_{1-3}alkyl; wherein R^1 may be optionally substituted on carbon by one or more methyl, ethyl, methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, dimethylamino, 2,2,2-trifluoroethoxy~~, phenyl~~ or cyclopropylmethoxy;

and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by one or more methyl, ethyl, acetyl, 2,2,2-trifluoroethyl or methoxyethyl;

R^2 is halo, cyano, C_{1-3}alkyl or C_{1-3}alkoxy;

p is 0-2; wherein the values of R^2 may be the same or different;

R^3 is hydrogen, halo or cyano;

R^4 is C_{2-6}alkyl;

R^5 is C_{1-6}alkyl or C_{2-6}alkenyl; wherein R^5 may be optionally substituted on carbon by one or more methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethoxy or cyclopropylmethoxy;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof~~;~~

~~vii) a compound of formula **(IG)** is selected from:~~



~~**(IG)**~~

~~wherein:~~

~~**R^1** is C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkylC_{1-3}alkyl, a heterocyclyl or heterocyclylC_{1-3}alkyl; wherein R^1 may be optionally substituted on carbon by one or more methyl, ethyl, methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, dimethylamino, 2,2,2-trifluoroethoxy, phenyl or cyclopropylmethoxy; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by one or more methyl, ethyl, acetyl, 2,2,2-trifluoroethyl or methoxyethyl;~~

~~**R^2** is halo, cyano, C_{1-3}alkyl or C_{1-3}alkoxy;~~

~~**p is 0-2; wherein the values of R^2 may be the same or different;**~~

~~**R^3 is hydrogen, halo or cyano;**~~

~~**R^4 is n-propyl or C_{4-6}alkyl;**~~

~~or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof~~.

Claim 2 **(currently amended)**: The ~~A~~ compound of formula **(I)** according to claim 1 which is a compound of formula **(IA)**, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 3 **(currently amended)**: The ~~A~~ compound of formula **(IA)** according to claim 2 selected from:

2-{4-[*N*-(2-ethoxyethyl)sulphamoyl]anilino}-4-(1,2-dimethylimidazol-5-yl)pyrimidine;

2-{4-[*N*-(*t*-butyl)sulphamoyl]anilino}-4-(1,2-dimethylimidazol-5-yl)pyrimidine;

2-{4-[*N*-(1-ethoxyprop-2-yl)sulphamoyl]anilino}-4-(1,2-dimethylimidazol-5-yl)pyrimidine;

2-{4-[*N*-(1-propoxyprop-2-yl)sulphamoyl]anilino}-4-(1,2-dimethylimidazol-5-yl)pyrimidine; and

2-{4-[*N*-(1-methylcyclopropyl)sulphamoyl]anilino}-4-(1,2-dimethylimidazol-5-yl)pyrimidine;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 4 **(currently amended)**: The ~~A~~ compound of formula **(I)** according to claim 1 which is a compound of formula **(IB)**, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 5 **(currently amended)**: The ~~A~~ compound of formula **(IB)** according to claim 4 selected from:

4-(1-ethyl-2-methylimidazol-5-yl)-2-{4-[*N*-(2-ethoxyethyl)sulphamoyl]anilino}pyrimidine; and

~~2-{4-[*N*-(2-isopropoxyethyl)sulphamoyl]anilino}-4-(1-ethyl-2-methylimidazol-5-yl)pyrimidine;~~

~~2-{4-[*N*-(2-propoxyethyl)sulphamoyl]anilino}-4-(1-ethyl-2-methylimidazol-5-yl)pyrimidine;~~

2-{4-[*N*-(1,1-dimethylprop-2-ynyl)sulphamoyl]anilino}-4-(1-ethyl-2-methylimidazol-5-yl)pyrimidine; ~~and~~

~~2-{4-[*N*-(2-vinyloxyethyl)sulphamoyl]anilino}-4-(1-ethyl-2-methylimidazol-5-yl)pyrimidine;~~

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 6 **(currently amended)**: The ~~A~~ compound of formula **(I)** according to claim 1 which is a compound of formula **(IC)**, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 7 **(currently amended)**: The ~~A~~ compound of formula **(IC)** according to claim 6, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof; wherein

R^1 is hydrogen, 2-methoxyethyl, methyl~~,~~ or 2-ethoxyethyl~~, 2-isopropoxyethyl, 2-propoxyethyl, 2-(cyclopropylmethoxy)ethyl, 3-(*t*-butoxy)propyl, 3-[2-(2-ethoxyethoxy)ethoxy]propyl, 3-(2-methoxyethoxy)propyl, carboxymethyl, *t*-butoxycarbonylmethyl, 2-hydroxyethyl, 2-(*N*-methylpyrrolidin-2-yl)ethyl, *N*-ethylpyrrolidin-2-ylmethyl, 2-pyrrolidin-1-ylethyl, 2-morpholinoethyl, 3-morpholinopropyl, *N*-benzylpiperidin-4-yl, 2-piperdin-1-ylethyl, 2-dimethylaminoethyl, 2-diethylaminoethyl or methoxycarbonylmethyl~~; and

R^2 is hydrogen or bromo;

provided that when R^1 is 2-methoxyethyl R^2 is not hydrogen.

Claim 8 **(currently amended)**: The ~~A~~ compound of formula **(IC)** according to claim 6 selected from:

4-(1-isopropyl-2-methylimidazol-5-yl)-2-{4-[*N*-(2-ethoxyethyl)sulphamoyl]anilino} pyrimidine; and

~~4-(1-isopropyl-2-methylimidazol-5-yl)-2-{4-[*N*-(2-isopropoxyethyl)sulphamoyl]anilino} pyrimidine;~~

~~4-(1-isopropyl-2-methylimidazol-5-yl)-2-{4-[*N*-(2-propoxyethyl)sulphamoyl]anilino} pyrimidine;~~

~~4-(1-isopropyl-2-methylimidazol-5-yl)-2-(4-{*N*-[2-(cyclopropylmethoxy)ethyl]sulphamoyl} anilino)pyrimidine; and~~

4-(1-isopropyl-2-methylimidazol-5-yl)-2-{4-[*N*-(methyl)sulphamoyl]anilino} pyrimidine;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 9 **(currently amended)**: The ~~A~~ compound of formula **(I)** according to claim 1 which is a compound of formula **(ID)**, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 10 **(currently amended)**: The ~~A~~ compound of formula **(ID)** according to claim 9, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof; wherein

R^1 is cyclopropyl, 2-methoxyethyl~~, 2-ethoxyethyl~~ or tetrahydrofur-2-ylmethyl;

R^2 is hydrogen; and

R^3 is ethyl~~, propyl~~ or isopropyl.

Claim 11 **(currently amended)**: The ~~A~~ compound of formula **(ID)** according to claim 9 selected from:

4-(1-isopropylimidazol-5-yl)-2-{4-[*N*-(cyclopropyl)sulphamoyl]anilino}pyrimidine;

4-(1-isopropylimidazol-5-yl)-2-{4-[*N*-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino} pyrimidine;

~~4-(1-propylimidazol-5-yl)-2-{4-[*N*-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine;~~

4-(1-ethylimidazol-5-yl)-2-{4-[*N*-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine; and

4-(1-isopropylimidazol-5-yl)-2-{4-[*N*-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 12 **(currently amended)**: The ~~A~~ compound of formula **(I)** according to claim 1 which is a compound of formula **(IE)**, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 13 **(currently amended)**: The ~~A~~ compound of formula **(IE)** according to claim 12, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof; wherein
R^1 is hydrogen or 2-methoxyethyl;
R^2 is fluoro;
p is 1;
R^3 is hydrogen; and
R^4 is methyl.

Claim 14 **(currently amended)**: The ~~A~~ compound of formula **(IE)** according to claim 12 selected from:
2-{4-[*N*-(2-methoxyethyl)sulphamoyl]-2-fluoroanilino}-4-(1,2-dimethylimidazol-5-yl)pyrimidine; and
2-(4-sulphamoyl-2-fluoroanilino)-4-(1,2-dimethylimidazol-5-yl)pyrimidine;
or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 15 **(currently amended)**: The ~~A~~ compound of formula **(I)** according to claim 1 which is a compound of formula **(IF)**, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 16 **(currently amended)**: The ~~A~~ compound of formula **(IF)** according to claim 15, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof; wherein
R^1 is methyl, 3-dimethylaminopropyl, 3-methoxypropyl, 3,3,3-trifluoropropyl~~,~~ or butyl~~, benzyl, tetrahydrofur-2-ylmethyl, 3-ethoxypropyl or 3-morpholinopropyl~~;
p is 0;
R^3 is hydrogen~~ or bromo~~;

R^4 is isopropyl; and
R^5 is methyl.

Claim 17 **(currently amended)**: The ~~A~~ compound of formula **(IF)** according to claim 15 selected from:
4-(1-isopropyl-2-methylimidazol-5-yl)-2-(4-mesylanilino)pyrimidine;
~~4-(1-isopropyl-2-methylimidazol-5-yl)-2-[4-(tetrahydrofur-2-ylmethylsulphonyl)anilino] pyrimidine;~~
~~4-(1-isopropyl-2-methylimidazol-5-yl)-2-[4-(3-ethoxypropylsulphonyl)anilino]pyrimidine;~~
4-(1-isopropyl-2-methylimidazol-5-yl)-2-[4-(3-methoxypropylsulphonyl)anilino]pyrimidine; and
4-(1-isopropyl-2-methylimidazol-5-yl)-2-[4-(3-*N,N*-dimethylaminopropylsulphonyl)anilino] pyrimidine;
or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claims 18-20 **(cancelled).**

Claim 21 **(currently amended)**: A pharmaceutical composition which comprises a compound of formula **(I)**, or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, according to claim 1 ~~any one of claims 1-20~~, in association with a pharmaceutically-acceptable diluent or carrier.

Claims 22-32 **(cancelled).**

Claim 33 **(previously presented)**: A method for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal in need thereof, which comprises administering to said animal an effective amount of a compound of formula **(I)** or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof as claimed in claim 1.

Claim 34 **(cancelled).**

Claim 35 **(currently amended)**: A method for treating ~~a disease or medical condition selected from cancer (solid tumours and leukaemias), fibroproliferative and differentiative disorders, psoriasis,~~ rheumatoid arthritis~~, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation,~~ in a warm-blooded animal in need thereof, which comprises administering to said animal an effective amount of a compound of formula **(I)** or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof as claimed in claim 1.

Claims 36-38 **(cancelled).**